Litcius/Paper detail

E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer

Hui Li, Shufen Zhao, Liwei Shen, Peige Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Gongjun Wang, Jing Lv, Wensheng Qiu

2021Aging34 citationsDOIOpen Access PDF

Abstract

BACKGROUND: E2F2 is a member of the E2F transcription factor family and has important but not fully understood biological functions in cancers. The biological role of E2F2 in gastric cancer (GC) also remains unclear. METHODS: We examined the expression levels of E2F2 in GC using publicly available datasets such as TIMER, Oncomine, GEPIA, UALCAN, etc., and in our patient cohort, using quantitative real-time PCR, western blotting, and immunohistochemistry. We further investigated the effects of E2F2 on phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling, autophagy, and the migration and invasion of GC cells by the wound healing assay, Transwell assay and transmission electron microscopy. RESULTS: through inhibition of PI3K/Akt/mTOR-mediated autophagy. CONCLUSION: High E2F2 expression was associated with the characteristics of invasive tumors and poor prognosis. E2F2 also had potential modulatory effects on tumor immunity. We discovered a novel function of E2F2 in the regulation of PI3K/Akt/mTOR-mediated autophagy and the downstream processes of cell migration and invasion.

Topics & Concepts

PI3K/AKT/mTOR pathwayAutophagyProtein kinase BCancerRPTORCancer researchDiscovery and development of mTOR inhibitorsChemistryMedicineApoptosisInternal medicineBiochemistryAutophagy in Disease and TherapyCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer
E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer | Litcius